Risks of diabetes mellitus and impaired glucose tolerance induced by intermittent versus continuous androgen-deprivation therapy for advanced prostate cancer.
- Author:
Sheng ZENG
1
;
Zhuo-Ping LI
1
;
Wei LI
1
;
Wei-Zhen PU
1
;
Peng LIU
1
;
Zhi-Fang MA
1
Author Information
1. Department of Urology, The First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, China.
- Publication Type:Journal Article
- Keywords:
continuous androgen-deprivation therapy;
diabetes mellitus;
impaired glucose tolerance;
intermittent androgen-deprivation therapy;
prostate cancer
- MeSH:
Aged;
Alcohol Drinking;
adverse effects;
Androgen Antagonists;
adverse effects;
therapeutic use;
Blood Glucose;
metabolism;
Body Mass Index;
Case-Control Studies;
Diabetes Mellitus;
chemically induced;
Glucose Intolerance;
chemically induced;
Glucose Tolerance Test;
Humans;
Hypertension;
complications;
Male;
Prostatic Neoplasms;
drug therapy;
pathology;
Retrospective Studies;
Risk Factors;
Smoking;
adverse effects
- From:
National Journal of Andrology
2017;23(7):598-602
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the correlation of intermittent androgen-deprivation therapy (IADT) and continuous androgen-deprivation therapy (CADT) for advanced prostate cancer (PCa) with the risks of secondary diabetes mellitus (DM) and impaired glucose tolerance (IGT).
METHODS:We conducted a retrospective case-control study of the advanced PCa patients treated by IADT or CADT in our hospital from January 2013 to December 2015. Based on the levels fasting blood glucose and 2-hour postprandial blood glucose, results of oral glucose tolerance test, and clinical symptoms of the patients, we statistically analyzed the IADT- or CADT-related risk factors for DM and IGT and the relationship of the body mass index (BMI), hypertension, smoking, and alcohol consumption with secondary DM and IGT.
RESULTS:IADT was given to 53 (46.5%) of the patients, aged (69.1 ± 4.3) years, and CADT to 61 (53.5%), aged (70.2 ± 5.7) years. No statistically significant differences were observed in clinical characteristics between the two groups of patients (P > 0.05). BMI, blood pressure, smoking and drinking exhibited no significant influence on the development of DM or IGT either in the IADT (P > 0.05) or the CADT group. The incidence of IGT was significantly lower in the IADT than in the CADT group (P = 0.03), but that of DM showed no statistically significant difference between the two groups (P = 0.64).
CONCLUSIONS:Compared with CADT, IADT has a lower risk of IGT and a higher safety in the treatment of advanced prostate cancer.
